Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital

Introduction: Cabazitaxel (CBZ) is used worldwide for castration-resistant prostate cancer after docetaxel treatment. In July 2014 the drug was approved in Japan with the same induction dose used for Caucasian patients. In this study, we examined and compared the results of an initial low-dose CBZ t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaya, Ryosuke, Okamura, Takehiko, Yanase, Takahiro, Nagai, Takashi, Moritoki, Yoshinobu, Kobayashi, Daichi, Akita, Hidetoshi, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Association of Rural Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983453/
https://www.ncbi.nlm.nih.gov/pubmed/32015778
http://dx.doi.org/10.2185/jrm.2019-004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983453/
https://www.ncbi.nlm.nih.gov/pubmed/32015778
http://dx.doi.org/10.2185/jrm.2019-004

Ejemplares similares